Skip to main content

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients with Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

Trial Status: Complete

This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Inclusion Criteria

  • Diagnosis of familial adenomatous polyposis (FAP) or attenuated familial adenomatous polyposis (AFAP), defined as at least one of the following: * Genetic diagnosis with confirmed APC mutation (Clinical Laboratory Improvement Act [CLIA] certified lab or research testing) * Obligate carrier * Clinical diagnosis of classic FAP with >= 100 colorectal adenomas status post colectomy and a family history of FAP * Clinical diagnosis of FAP, based on personal and family history; Note: This criterion requires documented review and agreement from either the study chair or the Cancer Prevention Network (CPN) lead investigator
  • Ability to understand and the willingness to sign a written informed consent document
  • Willing to discontinue taking nonsteroidal anti-inflammatory drugs (NSAIDS) for 30 days prior to initiation of and during intervention; exception: use of =< 81 mg daily or =< 650 mg weekly aspirin is allowed
  • Willing to discontinue smoking for the duration of study intervention
  • Willing to provide mandatory biospecimens as specified in the protocol
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1
  • Leukocytes (white blood cells [WBC]) >= 3,000/uL (>= 2,500/uL for African-American participants)
  • Platelet count >= 100 x 10^9/L
  • Hemoglobin >= 11.5 g/dL
  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
  • Alkaline phosphatase =< 1.5 x institutional upper limit of normal (ULN)
  • Aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) =< 2 x institutional upper limit of normal (ULN)
  • Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 2 x institutional upper limit of normal (ULN)
  • Creatinine =< institutional upper limits of normal (ULN)
  • Urinary testing results within institutional limits of normal or deemed clinically insignificant
  • Spigelman 2‐3
  • Not pregnant or breast feeding; Note: the effects of erlotinib (Tarceva ) on the developing human fetus at the recommended therapeutic dose are unknown; for this reason, women of child‐bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; breastfeeding should be discontinued if the mother is treated with erlotinib
  • Willing to use adequate contraception to avoid pregnancy or impregnation until 2 weeks after discontinuing study agent

Exclusion Criteria

  • Any prior treatment with erlotinib or other agent whose primary mechanism of action is known to inhibit EGFR
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib
  • Use of potent CYP3A4 inhibitors, including but not limited to ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, voriconazole, and grapefruit or grapefruit juice
  • Use of potent CYP3A4 inducers, including but not limited to rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's wort
  • Use of any other investigational agents =< 12 weeks prior to pre-registration
  • Uncontrolled intercurrent illness or recent surgical procedure that in the opinion of the investigative team would limit compliance with study requirements, including, but not limited to: * Ongoing or active infection * Symptomatic congestive heart failure * Myocardial infarction =< 6 months prior to intervention * Severely impaired lung function * Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with study intervention * Diagnosed liver disease, such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis * Unstable angina pectoris * Cardiac arrhythmia * Psychiatric illness/social situations
  • History of invasive malignancy =< 3 years prior to pre-registration; exception: adequately treated carcinoma of the cervix, carcinoma in situ, or basal or squamous cell carcinomas of the skin
  • Individuals on anticoagulation medications who cannot safely discontinue the medication for at least 48 hours prior to the study endoscopy, as determined by the study investigator and/or participant’s primary healthcare provider
  • History of any upper gastrointestinal (GI) surgery that does not permit access to or evaluation of a 10 cm segment of the duodenum that includes the duodenal bulb, i.e. Whipple procedure or similar
  • Histologically-confirmed high grade dysplasia (HGD), cancer, or polyp burden that is not quantifiable
  • Regular (>= 2 times per week) use of drugs that alter the pH of the gastrointestinal tract (GI) tract, such as proton pump inhibitors (PPI) and antacids; exceptions: individuals who use prescription PPIs and have approval from their primary health care provider to replace the PPI with an H2 receptor agonist, i.e. ranitidine, for the duration of the trial will be eligible
  • Gastrointestinal bleeding; note that the presence of any symptoms (dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia, abdominal pain) will require clinical assessment to rule out gastrointestinal bleeding


Mayo Clinic in Arizona
Contact: Jewel Samadder
Phone: 480-301-8000


Ann Arbor
University of Michigan Comprehensive Cancer Center
Contact: Elena Martinez Stoffel
Phone: 734-647-1417


Mayo Clinic in Rochester
Contact: Paul John Limburg
Phone: 507-284-2511


Cleveland Clinic Foundation
Contact: Carol Ann Burke
Phone: 216-444-6864


University of Pittsburgh Cancer Institute (UPCI)
Contact: Rohit Das
Phone: 412-864-7091

Puerto Rico

San Juan
University of Puerto Rico
Contact: Marcia R. Cruz-Correa
Phone: 787-772-8300


M D Anderson Cancer Center
Contact: Eduardo Vilar-Sanchez
Phone: 713-745-1836


Salt Lake City
Huntsman Cancer Institute / University of Utah
Contact: Priyanka Kanth
Phone: 801-581-7803


I. To assess the mean percent change in duodenal polyp burden (sum of diameters from all polyps) from baseline to 6 months post-intervention for familial adenomatous polyposis (FAP) subjects receiving weekly erlotinib hydrochloride (erlotinib).

II. To assess the grade 2/3 adverse event rate in this population and compare it to historical data.


I. To evaluate all adverse events at least possibly attributed to weekly erlotinib.

II. To assess the absolute and percent change in duodenal polyp number from baseline to 6 months.

III. To assess the absolute and percent changes in lower gastrointestinal polyp burden and number for the subset of participants with ileal pouch anal anastomosis (IPAA) or ileo-rectal anastomosis with rectal stump.

IV. To assess the absolute and percent change in desmoid tumor size in participants who have baseline and follow up computed tomography (CT)s performed as part of their standard of care.

V. Gene expression profiles in duodenal adenomas and uninvolved tissue will be compared between baseline and endpoint samples using negative binomial statistics (DESeq2).

VI. Identify differentially expressed genes between duodenal polyps and uninvolved tissue at endpoint compared to baseline.

VII. Evaluate the effect of weekly erlotinib on EGFR and Wnt target gene expression in duodenal adenomas.

VIII. Evaluate the effect of weekly erlotinib on immune response signaling in duodenal adenomas and uninvolved tissue.


Patients receive erlotinib hydrochloride orally (PO) once weekly. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days.

Trial Phase Phase II

Trial Type Prevention

Lead Organization
Mayo Clinic in Rochester

Principal Investigator
Niloy Jewel Samadder

  • Primary ID MAY2016-07-01
  • Secondary IDs NCI-2016-01674, N01-CN-2012-00042
  • ID NCT02961374